Navigation Links
Genomatix, USU and HJF execute a CRADA: Prostate cancer prognostic marker discovery by NGS
Date:8/22/2011

Genomatix Software, the Uniformed Service University of the Health Sciences (USU), and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) have entered into a Cooperative Research and Development Agreement (CRADA) to extend their collaborative endeavors in prostate disease research. The aim of the joint research will be to differentiate patients with favorable versus poor prognosis at the time of diagnosis and primary treatment using definitive genetic markers. The majority of prostate cancer cases in PSA-screened population fall into a so called "grey zone" of prostate cancer where outcome is extremely difficult to predict at the time of diagnosis. The CRADA extends a long and already fruitful collaboration (Masuda, Werner et al, J Mol Biol. 353, 763-771 2005; Furusato et al, PCPD. 11, 194-97, 2008) with USU's Center for Prostrate Disease Research (CPDR). This collaboration combines CPDR's translational research resources and expertise and Genomatix' data analysis expertise in teasing out novel androgen receptor binding sites in the genome and analyzing prostate cancer metastasis using prostate cancer model systems and clinical specimens.

"This CRADA is a natural extension of accomplishments we have already achieved together," said Dr. Thomas Werner, founder of Genomatix Software. "Next Generation Sequencing opens a new dimension in biomarker research and will allow a finer grained, unbiased look at some of the genomic mechanisms behind prostate disease, thus providing the opportunity for the discovery of new prognostic biomarkers, some of which also may be targets for therapeutic intervention and treatment monitoring."

Dr. Shiv Srivastava; CPDR Co-director, Scientific Director, and Professor of Surgery at USU added: "Our work to date with Genomatix has been very productive. People from both our organizations have already established quality working relationships. Leveraging this and moving forward together into a technology as ground breaking as Next Generation Sequencing holds great promise for significant progress in prostate disease research."


'/>"/>

Contact: Korbinian Grote
grote@genomatix.de
Genomatix Software GmbH
Source:Eurekalert

Related biology news :

1. Genetic risk factors may tailor prostate cancer screening approaches
2. Prostate cancer spurs new nerves
3. Men with wives, significant others more likely to be screened for prostate cancer
4. New lab evidence suggests preventive effect of herbal supplement in prostate cancer
5. Dana-Farber oncologists present at ASCO GU -- predict prostate cancer survival using Source MDx test
6. Freezing prostate cancer does a mans body good
7. New medications show promise in treating drug-resistant prostate cancer
8. New drug shows promise in treating drug-resistant prostate cancer
9. Agent Orange exposure increases veterans risk of aggressive recurrence of prostate cancer
10. 3-D research model tackles prostate cancer spread
11. Gene activity reveals dynamic stroma microenvironment in prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , February 8, 2016 ... platform which presents innovation for clients, comfort and ... called VoiceKey. --> Worldcore is ... innovation for clients, comfort and unbeatable security, with ... --> Worldcore is the first ...
(Date:2/4/2016)... 2016 The field of Human Microbiome ... most popular hubs of the biotechnology industry. While ... studies of human microbiota, have garnered a lot ... microbiome space has literally exploded in terms of ... report focuses on biomedical aspects of research, development, ...
(Date:2/3/2016)... 3, 2016 --> ... report "Automated Fingerprint Identification System Market by Component (Hardware ... (Banking & Finance, Government, Healthcare, and Transportation) and Geography ... market is expected to be worth USD 8.49 Billion ... 2015 and 2020. The transformation and technology evolution from ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... 11, 2016  Vermillion, Inc. (NASDAQ: VRML ), ... announced the formation of the Steering Committee for its ... --> Pelvic masses can present physicians and ... Once pregnancy is ruled out, pelvic masses may include ... endometriosis, benign ovarian tumors and gastrointestinal and urinary tract ...
(Date:2/11/2016)... -- Wellcentive today announced it has been selected by FamilyCare ... community care organization (CCO) with more than 130,000 ... and care management solutions and services. Wellcentive,s capabilities ... managers, analysts and care managers while providing insight ... members. Oregon . ...
(Date:2/11/2016)... Feb. 11, 2016   BioInformant announces the ... Cell Research Products, Opportunities, Tools, and Technologies – Market ... The first ... stem cell industry, BioInformant has more than a decade ... cell market, by stem cell type. This powerful 175 ...
(Date:2/10/2016)... MONTREAL , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. ... is pleased to announce that Mitsui & Co. Ltd., ... bio-based succinic acid plant, is investing an additional CDN$25 ... equity, increasing its stake from 30% to 40%.  Mitsui ... of bio-succinic acid produced in Sarnia ...
Breaking Biology Technology: